Particle therapy achieves 48% three-year survival in prospective T3N0M0 NSCLC registry
A Japanese prospective registry reported 48.1% three-year overall survival and 5.2% grade ≥3 toxicity after proton or carbon-ion therapy for T3N0M0 NSCLC.
A Japanese prospective registry reported 48.1% three-year overall survival and 5.2% grade ≥3 toxicity after proton or carbon-ion therapy for T3N0M0 NSCLC.
In synchrotron UHDR proton and carbon-ion beams, dose-averaged dose rate better described chamber recombination than conventional field-averaged metrics.
A particle-therapy second-check platform modeled delivery and variable RBE, but its reported proton dose comparison achieved 84.9% gamma agreement and required review.
New ESTRO-EPTN recommendations define validated, risk-based pathways for introducing independent dose calculation and machine log-file QA in scanned particle therapy.
After 10 years, EPTN is shifting its focus toward prospective registries, adaptive therapy, harmonised QA and stronger clinical evidence.
A portable 49 mT MRI system operated during proton and carbon-ion delivery with stable imaging and minimal dosimetric impact.
Upright gantry-less RT could reduce system complexity and improve access, but imaging, immobilization and limited clinical evidence remain major barriers.
Modern dosimetry can meet historical accuracy requirements, but tighter geometric precision and particle-specific uncertainties increasingly determine treatment accuracy.
Protons, helium and carbon ions suppressed migration and invasion that increased after photon irradiation, with helium showing a favorable biological-dosimetric balance.
Carbon ions show the strongest signal in radioresistant gynecologic tumors, while proton evidence centers on adjuvant treatment and reirradiation.
AI can automate particle planning, dose prediction, adaptation and quality assurance, but limited data and validation still constrain clinical adoption.
NanOx predictions differed from measured laryngeal cancer cell survival by 20–37% and overestimated the distal biological gradient.
A scanned helium beamline achieved submillimetre range accuracy and generally ≤3% dose agreement, supporting further translation toward clinical helium therapy.
Radioactive carbon-11 beams enabled PET-guided range adjustment during irradiation, with biological outcomes matching insufficient, optimal and excessive beam penetration.
A translational review proposes shared reporting and quality-assurance principles for model-dependent biological dose in proton, carbon-ion and boron neutron capture therapy.